CANCER RESEARCH UK

(Form to be on hospital/institution headed paper with CR UK logo included)

UKALL14: A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

Patient Information Sheet:

Additional genetic testing (stored bone marrow sample)

Version 1.0 09.09.2015

You have previously agreed to take part in the UKALL14 study. We would now like to invite you to take

part in some additional research that is being carried out alongside the UKALL14 Study. Taking part in

this extra research is optional, and will not affect your taking part in the UKALL14 study.

Before you decide whether or not to take part, one of your doctor's team will go through this patient

information sheet with you and answer any questions you may have so that you fully understand why we

are carrying out this research and what it would involve for you.

Please take the time to read the information carefully and talk to others about the study if you wish. Ask

us if there is anything you don't understand or if you would like more information and take your time to

decide whether or not you wish to take part.

What is the purpose of the study?

The development of ALL is not well understood. More specifically the genetic changes that lead to the

development of ALL have not been very well characterised.

Previous studies have looked at the genetic changes within leukaemic (cancerous) cells. They have

shown us why some patients respond to treatment better than others. As part of your standard care and

participation in the UKALL14 study your leukaemic cells are tested for 'cytogenetic abnormalities'.

The purpose of this study is to look at whether there are any genetic changes that ALL patients have in

common in their non-leukaemic (non-cancerous) cells. This may help us understand why some adults

develop ALL, but others do not.

Why have I been invited?

You have been invited to take part in the study because you previously consented to take part in the

UKALL14 study. This study is providing us with valuable data on how best to treat patients with ALL.

modified for **UKALL14** on 09.09.2015 v1.0 PIS Template Version 2.1 10/Sep/2012

Page 1 of 3

CANCER RESEARCH UK

Do I have to take part?

No. It is up to you to decide whether or not to take part in the study. We will describe what would be

involved and go through this patient information sheet with you, which is yours to take away so that you

have the opportunity to read it carefully and discuss the study with others if you wish. If you decide to

take part, we will ask you to sign a consent form. You are free to withdraw at any time, without giving a

reason. If you decide not to take part, or later to withdraw, this will not affect the standard of care you

receive. It will also not affect your participation and treatment on the main UKALL14 trial.

What will happen to me if I take part?

If you agree to take part, you will be asked to sign a consent form. By signing the consent form you are

agreeing to allow a sample of your cells to be used to carry out genetic testing. In this case, the tests will

look at your DNA, rather than the DNA of your leukaemic cells.

You have previously agreed to samples of bone marrow being sent to the UCL Cancer Institute for testing

to see if your disease has responded to treatment. With your permission, left-over material from one of

the samples you have already given will be used for the genetic study.

What will happen to any samples I give?

As explained above, we are asking you to allow us to carry out research using a sample of your bone

marrow previously collected in the UKALL14 study, which is currently in storage at UCL Cancer Institute

in London.

This sample will be taken out of storage at the central laboratory at the UCL Cancer Institute and

processed to isolate your DNA. We will then perform various genetic tests. The results of these tests will

be studied alongside those of other ALL patients, to see whether we can identify genes that people who

develop ALL have in common.

The results of tests performed will be held on a research database for use in medical research only. The

results of your genetic testing will be linked with the genetic tests performed on your leukemic sample as

part of the main UKALL14 trial.

Any extra material may be stored for use in future research which has been approved by an Ethics

Committee. If you do not wish for this to be done, the sample will be disposed of in a way which meets

the European Union regulations and directives for disposal of genetic material. You may withdraw your

consent at any time, in which case the extra material will be destroyed.

modified for **UKALL14** on 09.09.2015 v1.0 PIS Template Version 2.1 10/Sep/2012

Page 2 of 3

CANCER RESEARCH UK

What are the possible benefits of taking part?

The results of this genetic testing will not influence the treatment you are about to or have received. The information we get from this study will, however, help improve our understanding of with the link between genes and ALL in adults.

What will happen if I change my mind?

You can withdraw from the study at any time without giving reason. Any stored samples that can be identified as yours will be destroyed if you wish.

What will happen to the results of the tests?

We will not feedback the results found from the genetic tests to patients and their families. The results from the study will be made available to the public through scientific publications without disclosing your identity.

Thank you

Thank you for considering taking part in this study and for taking the time to read this patient information sheet, which is yours to keep. If you decide to take part in the study, you will also be given a copy of your signed consent form.